Outcomes for patients undergoing transcatheter aortic valve replacement with ascending aorta dilation
Dejing Feng,Jie Zhao,Guannan Niu,Yuxuan Zhang,Can Wang,Yang Chen,Zheng Zhou,Hongliang Zhang,Zhenyan Zhao,Yunqing Ye,Zhe Li,Haiyan Xu,Moyang Wang,Yongjian Wu
DOI: https://doi.org/10.1016/j.ijcard.2024.131948
IF: 4.039
2024-03-12
International Journal of Cardiology
Abstract:Background We aim to compare the short and long-term outcomes for aortic stenosis (AS) patients undergone TAVR with and without ascending aorta dilation (AAD). Methods Consecutive patients diagnosed with native severe AS who underwent TAVR from September 2012 to September 2021 were enrolled. They were stratified into the moderate/severe dilation group (greatest ascending aorta width ≥ 45 mm) and the non/mild dilation group. Survival outcomes were illustrated using Kaplan-Meier curves and evaluated with the log-rank test. Data from patients with CT follow-up of >6 months was used to investigate the progression rate of AAD. Results The study cohort comprised 556 patients, with a mean age of 75.52 ± 7.30 years. Among them, 107 patients (19.2%) had a moderate/severe AAD (≥45 mm), with an average diameter of 48.58 mm (±2.82). During hospitalization, both groups witnessed two cases of ascending aortic dissection (1.8% vs 0.5%, P = 0.380). The median follow-up duration was 3.92 years (95% CI: 3.79–4.04 years). No deaths were caused by aortic events and no patients experienced a new aortic dissection. The AAD cohort's 4-year all-cause and cardiovascular mortality rates were not significantly different to the non-dilation group's (log-rank test, P = 0.109 and P = 0.698, respectively). Follow-up CT data revealed that the rate of aortic dilation progression in the moderate/severe dilation group was not significantly different from that in the non/mild group (0.0 mm/year, 25–75%th: −0.3-0.2 vs 0.1 mm/year, 25–75%th: -0.3-0.4, P = 0.394). Conclusion This study found no significant difference regarding short-term and long-term outcomes in AS patients with/without moderate/severe AAD undergoing TAVR.
cardiac & cardiovascular systems